LBRX
LB Pharmaceuticals Inc
$24.30
+0.29%
2026-02-27
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Key Fundamentals
Forward P/E
-6.90
EPS (TTM)
$-3.13
ROE
-15.7%
Profit Margin
0.0%
Debt/Equity
1.18
Price/Book
2.59
Market Cap
$885.8M
Avg Volume (10D)
154K
Recent Breakout Signals
No recent breakout signals detected for LBRX.
Recent Price Range (60 Days)
60D High
$25.60
60D Low
$17.34
Avg Volume
313K
Latest Close
$24.30
Get breakout alerts for LBRX
Sign up for Breakout Scanner to receive daily notifications when LBRX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
LB Pharmaceuticals Inc (LBRX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors LBRX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. LBRX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.